Rick E Winningham Theravance Biopharma, Inc. (TBPH) insider trading activity

Rick E Winningham is CHIEF EXECUTIVE OFFICER of Theravance Biopharma, Inc.. Currently has a direct ownership of 1.65 Million shares of TBPH, which is worth approximately $28.7 Million. The most recent transaction as insider was on Nov 20, 2022, when has been sold 15,804 shares (Ordinary Shares) at a price of $10.85 per share, resulting in proceeds of $171,473. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.65M

3.88% 3M change

8.84% 12M change

Total Value Held $28.7 Million

Rick E Winningham Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 20 2022	SELL Payment of exercise price or tax liability	$171,473 $10.85 p/Share	15,804 Reduced 1.11%	1,409,797 Ordinary Shares
Aug 19 2022	SELL Payment of exercise price or tax liability	$147,609 $9.34 p/Share	15,804 Reduced 1.1%	1,424,784 Ordinary Shares
May 20 2022	SELL Payment of exercise price or tax liability	$96,358 $8.74 p/Share	11,025 Reduced 0.76%	1,440,588 Ordinary Shares
Feb 25 2022	BUY Grant, award, or other acquisition	-	170,000 Added 10.5%	1,449,300 Ordinary Shares
Feb 18 2022	SELL Payment of exercise price or tax liability	$218,243 $9.61 p/Share	22,710 Reduced 1.74%	1,279,300 Ordinary Shares
Nov 19 2021	SELL Payment of exercise price or tax liability	$95,337 $8.36 p/Share	11,404 Reduced 0.87%	1,302,010 Ordinary Shares
Aug 20 2021	SELL Payment of exercise price or tax liability	$160,226 $14.05 p/Share	11,404 Reduced 0.86%	1,313,414 Ordinary Shares

May 20 2021	SELL Payment of exercise price or tax liability	$202,991 $17.8 p/Share	11,404 Reduced 0.85%	1,324,818 Ordinary Shares
Feb 20 2021	SELL Payment of exercise price or tax liability	$2,073,439 $18.79 p/Share	110,348 Reduced 7.64%	1,334,821 Ordinary Shares
Feb 08 2021	BUY Grant, award, or other acquisition	-	170,000 Added 10.53%	1,445,169 Ordinary Shares
Nov 20 2020	SELL Payment of exercise price or tax liability	$240,011 $17.21 p/Share	13,946 Reduced 1.08%	1,275,169 Ordinary Shares

Also insider at

JAZZ

Jazz Pharmaceuticals plc Healthcare

Director

REW